跳转至内容
Merck

C2180000

桂利嗪

European Pharmacopoeia (EP) Reference Standard

别名:

1-反式-肉桂基-4-二苯基甲基哌嗪

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C26H28N2
CAS号:
分子量:
368.51
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

cinnarizine

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

SMILES 字串

C1CN(CCN1C\C=C\c2ccccc2)C(c3ccccc3)c4ccccc4

InChI

1S/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2/b13-10+

InChI 密鑰

DERZBLKQOCDDDZ-JLHYYAGUSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Cinnarizine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

相關產品

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Anne T Larsen et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 48(1-2), 339-350 (2012-11-28)
The in vivo performance of self-nanoemulsifying drug delivery systems (SNEDDSs) with different in vitro physicochemical properties were determined with the purpose of elucidating the parameters determining the in vivo performance of SNEDDSs. The in vitro characterisation included the use of
P Y Cezarino et al.
Climacteric : the journal of the International Menopause Society, 14(4), 492-496 (2011-03-24)
To evaluate the effectiveness and safety of cinnarizine in the treatment of menopausal symptoms. A total of 100 climacteric and symptomatic women participated in a double-blind, placebo-controlled study. They were divided into two groups of the same size: Gcin, intake
Mohamed A Alhnan et al.
International journal of pharmaceutics, 416(1), 55-60 (2011-06-18)
Poorly water soluble basic drugs are very sensitive to pH changes and following dissolution in the acidic stomach environment tend to precipitate upon gastric emptying, which leads to compromised or erratic oral bioavailability. In this work, we show that the
Amnon Gil et al.
Clinical neuropharmacology, 35(1), 37-39 (2011-12-06)
The objective of the study was to compare the efficacy of transdermal scopolamine and cinnarizine in the prevention of seasickness and their adverse reactions. Seventy-six naval crew members participated in a double-blind, randomized, crossover study. On 2 voyages, they were
Tri-Hung Nguyen et al.
Journal of controlled release : official journal of the Controlled Release Society, 153(2), 180-186 (2011-04-19)
This study is the first to demonstrate the ability of nanostructured liquid crystal particles to sustain the absorption of a poorly water soluble drug after oral administration. Cubic (V(2)) liquid crystalline nanostructured particles (cubosomes) formed from phytantriol (PHY) were shown

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门